AREVA
Live / Registered — Registered (as of 06 Oct 2026)
What this means for you
Registered since 06 Oct 2026. The owner can stop confusingly similar uses in the classes it covers; it stays on the register as long as the owner keeps up the maintenance filings (next due by 06 Oct 2032: the §8 declaration of use).
Record
- Serial number
- 98466263
- Registration number
- 8487303
- Mark type
- Design + words
- Filed
- 25 Mar 2024
- Published for opposition
- 31 Dec 2024
- Registered
- 06 Oct 2026
- Next maintenance filing
- §8 declaration of use, due by 06 Oct 2032 (grace period to 06 Apr 2033)
- Attorney of record
- Michael S. Hargis
Goods and services
- Class 005 — Pharmaceuticals: House mark for pharmaceutical preparations for the treatment of cancer, heart failure, heart disease, and hypertension; house mark for pharmaceutical preparations for use in gene therapy; house mark for pharmaceutical preparations for the treatment of cancer, heart failure, heart disease, and hypertension, in the form of oncology injectables and oral solids
Owner
- Areva Pharmaceuticals Inc., Georgetown, IN, US
- Areva Pharmaceuticals Inc., Georgetown, IN, US
- Areva Pharmaceuticals Inc., Georgetown, IN, US
Board proceedings on this mark
- Extension of Time to Oppose No. 98466263 — FAREVA S.A. v. Areva Pharmaceuticals Inc., filed 24 Jan 2025 (Terminated)
Prosecution history
- 06 Oct 2026 — NOTICE OF REGISTRATION CONFIRMATION EMAILED
- 06 Oct 2026 — REGISTERED-PRINCIPAL REGISTER
- 17 Sept 2026 — NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
- 17 Sept 2026 — ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
- 11 Sept 2026 — AMENDMENT FROM APPLICANT ENTERED
- 11 Sept 2026 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 11 Sept 2026 — ASSIGNED TO LIE
- 09 Sept 2026 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
- 01 Jun 2026 — APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
- 01 Jun 2026 — APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
- 13 Mar 2026 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
- 13 Mar 2026 — NON-FINAL ACTION E-MAILED
- 13 Mar 2026 — SU - NON-FINAL ACTION - WRITTEN
- 03 Mar 2026 — STATEMENT OF USE PROCESSING COMPLETE
- 22 Apr 2025 — USE AMENDMENT FILED